Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN2480 combinations in advanced nonhematologic malignancies
NCT02327169Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 4
01
Overview
Phase 1, open-label trial of tovorafenib in Non-hematologic malignancy, sponsored by Millennium Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events up to 13 months, Number of Participants With Dose-Limiting Toxicities and 2 more. Started Jan 2015; status: completed.
02
Drugs
tovorafenib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NCT02327169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327169.